07:00 , May 16, 2016 |  BC Week In Review  |  Company News

Hebrew University of Jerusalem, BioTheryX deal

The university’s Yissum Research Development Co. and BioTheryX partnered to develop and commercialize casein kinase 1 alpha ( CSNK1A ; CKI-alpha ) inhibitors to treat hematologic and solid malignancies. The collaboration will initially focus on...
07:00 , Oct 11, 2012 |  BC Innovations  |  Strategy

Leukemia team building

The Leukemia & Lymphoma Society has announced its first research partnership with a large biopharma company-a four-year, multimillion-dollar deal with Celgene Corp. to solicit and fund proposals from academics and smaller biotechs. The not-for-profit organization...
08:00 , Dec 13, 2010 |  BC Week In Review  |  Company News

BioTheryX board of directors update

BioTheryx Inc. , Chappaqua, N.Y.   Business: Cancer   Appointed: Louis DeGennaro, chief mission officer of The Leukemia & Lymphoma Society  ...
08:00 , Dec 6, 2010 |  BC Week In Review  |  Financial News

BioTheryX completes venture financing

BioTheryX Inc. , Chappaqua, N.Y.   Business: Cancer   Date completed: 11/30/10   Type: Venture financing   Raised: $4.5 million   Investor: Leukemia & Lymphoma Society  ...